Business Description
Lipum AB
ISIN : SE0015660899
Compare
Compare
Traded in other countries / regions
LIPUM.Sweden IPO Date
2021-04-22Description
Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. TheĀ candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.09 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | -0.3 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -2.1 | |||||
| 3-Year EPS without NRI Growth Rate | -2.1 | |||||
| 3-Year FCF Growth Rate | -4.3 | |||||
| 3-Year Book Growth Rate | -8.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.72 | |||||
| 9-Day RSI | 33.51 | |||||
| 14-Day RSI | 41.8 | |||||
| 6-1 Month Momentum % | 120.9 | |||||
| 12-1 Month Momentum % | 82.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.97 | |||||
| Quick Ratio | 3.97 | |||||
| Cash Ratio | 0.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.6 | |||||
| Shareholder Yield % | -26.95 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -176.66 | |||||
| ROA % | -124.63 | |||||
| ROIC % | -228.63 | |||||
| ROC (Joel Greenblatt) % | -21149.13 | |||||
| ROCE % | -162.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.36 | |||||
| Price-to-Tangible-Book | 6.36 | |||||
| EV-to-EBIT | -7.75 | |||||
| EV-to-EBITDA | -7.76 | |||||
| EV-to-FCF | -3.92 | |||||
| Price-to-Net-Current-Asset-Value | 6.38 | |||||
| Earnings Yield (Greenblatt) % | -12.91 | |||||
| FCF Yield % | -25.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Lipum AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -3.1 | ||
| Beta | -0.34 | ||
| Volatility % | 65.11 | ||
| 14-Day RSI | 41.8 | ||
| 14-Day ATR (kr) | 0.970187 | ||
| 20-Day SMA (kr) | 15.39 | ||
| 12-1 Month Momentum % | 82.14 | ||
| 52-Week Range (kr) | 5.5 - 18.4 | ||
| Shares Outstanding (Mil) | 21.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lipum AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lipum AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lipum AB Frequently Asked Questions
What is Lipum AB(OSTO:LIPUM)'s stock price today?
The current price of OSTO:LIPUM is kr14.30. The 52 week high of OSTO:LIPUM is kr18.40 and 52 week low is kr5.50.
When is next earnings date of Lipum AB(OSTO:LIPUM)?
The next earnings date of Lipum AB(OSTO:LIPUM) is 2025-02-28.
Does Lipum AB(OSTO:LIPUM) pay dividends? If so, how much?
Lipum AB(OSTO:LIPUM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers